Rat studies showed that Biobran/MGN-3 treatment significantly protects against D-GalN-induced liver injury and hepatitis [57], and Biobran/MGN-3 of low molecular fraction also protects against acute liver injury through the inhibition of JNK/MAPK and NF-кB expression [58]. Here, MAPK8 is linked to Hepatitis.